Abstract:Primary central nervous system germ cell tumors (CNS GCTs) are part of the GCTs in children and adults. This tumor entity presents with geographic variation, age, and sex predilection. There are two age peaks of incidence distribution at the first few months of life and in adolescence. CNS GCTs are heterogeneous in histopathological subtypes, locations, and tumor marker (AFP, β-hCG) secretions. In the WHO CNS tumor classification, GCTS are classified as germinoma and nongerminomatous GCT (NGGCT) with different subtypes (including teratoma). Excluding mature teratoma, the remaining NGGCTs are malignant (NGMGCT). In teratoma, growing teratoma syndrome and teratoma with somatic-type malignancy should be highlighted. The common intracranial locations are pineal region, neurohypophysis (NH), bifocal pineal-NH, basal ganglia, and cerebral ventricle. Above 50% of intracranial GCTs (IGCTs) present obstructive hydrocephalus. Spinal tumors are rare. Age, locations, hydrocephalus, and serum/CSF titer of β-hCG correlate with clinical manifestations. Delayed diagnosis is common in tumors arising in neurohypophysis, bifocal, and basal ganglia resulting in the increasing of physical dysfunction and hormonal deficits. Staging work-up includes CSF cytology for tumor cells and contrast-enhanced MRI of brain and spine for macroscopic metastasis before treatment commences. The therapeutic approach of CNS GCTs integrates locations, histopathology, staging, tumor marker level, and therapeutic classification. Treatment strategies include surgical biopsy/excision, chemotherapy, radiotherapy (single or combination). Secreting tumors with consistent imaging may not require histopathological diagnosis. Primary germinomas are highly radiosensitive and the therapeutic aim is to maintain high survival rate using optimal radiotherapy regimen with/without chemotherapy combination. Primary NGNGCTs are less radiosensitive. The therapeutic aim is to increase survival utilizing more intensive chemotherapy and radiotherapy. The negative prognostic factors are residue disease at the end of treatment and serum or CSF AFP level >1000 ng/mL at diagnosis. In refractory or recurrent NMGGCTs, besides high-dose chemotherapy, new therapy is necessary. Molecular profiling and analysis help for translational research. Survivors of pediatric brain tumors frequently experience cancer-related cognitive dysfunction, physical disability, pituitary hormone deficiency, and other CNS complications after cranial radiotherapy. Continuous surveillance and assessment may lead to improvements in treatment protocols, transdisciplinary interventions, after-treatment rehabilitation, and quality of life.

Pathogenesis of central nervous system germ cell tumors

Advances in genetic abnormalities, epigenetic reprogramming, and immune landscape of intracranial germ cell tumors

Epid-36. Clinical Features Of 614 Primary Intracranial Germ Cell Tumors: An 15-Year Experience Of A Single Center In China

Recent advances in molecular biology and treatment strategies for intracranial germ cell tumors

Brain and Spinal Tumors Originating from the Germ Line Cells

Intracranial Germ Cell Tumors in Pediatric and Adolescent Patients in China: Systematic Review and Meta-Analysis

10121-BT-8 CLINICOPATHOLOGICAL ANALYSIS OF CENTRAL NERVOUS SYSTEM GERM CELL TUMORS -387CASES IN THE JCCG COHORT AND THE IGCT CONSORTIUM COHORT

Novel molecular subtypes of intracranial germ cell tumors expand therapeutic opportunities

Whole‐exome sequencing has revealed novel genetic characteristics in intracranial germ cell tumours in the Chinese

Update on MRI in Pediatric Intracranial Germ Cell Tumors—the Clinical and Radiological Features

Grading System for Diagnosis and Treatment of Intracranial Nongerminomatous Malignant Germ Cell Tumors

Genome-wide methylation profiles in primary intracranial germ cell tumors indicate a primordial germ cell origin for germinomas

Germ cell tumors of the central nervous system: A brief review and site-specific considerations

Recent advances in understanding the etiology and pathogenesis of pediatric germ cell tumors

CNS Germ Cell Tumors: Molecular Advances, Significance in Risk Stratification and Future Directions

The Treatment and Prognosis of Primary Pediatric Intracranial Nongerminomatous Malignant Germ Cell Tumors

Intracranial germ cell tumors: a view of the endocrinologist

Biomarkers for risk-based treatment modifications for CNS germ cell tumors: Updates on biological underpinnings, clinical trials, and future directions

Molecular Pathology and Targeted Therapies for Personalized Management of Central Nervous System Germinoma

Pituitary Dysfunction in Patients with Intracranial Germ Cell Tumors Treated with Radiotherapy

Individualized treatment of intracranial germ cell tumors